Effects of Androgen Receptor Overexpression in Prostate Cancer

October 2013

Paula Vartiainen

androgen receptor AR dihydrotestosterone DHT R1881 hormone-independent prostate cancer

TLDR Androgen receptor overexpression can increase prostate cancer cell growth even without hormones.

The study investigated the effects of androgen receptor (AR) overexpression in prostate cancer, focusing on cell proliferation and AR translocation to the nucleus. Using two AR overexpressing and two control LNCaP derived cell strains, the research found that AR overexpression led to increased proliferation, especially in 10 nM DHT and 1 nM R1881 conditions, and sustained proliferation even in starvation conditions. The AR translocation to the nucleus occurred within an hour and was more efficient in overexpressing strains, correlating with AR expression levels. These findings suggested that AR overexpression enhanced cell proliferation and nuclear translocation efficiency, contributing to the progression of prostate cancer.

View this study on trepo.tuni.fi →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community My Theory Regarding a Cause and Cure for Androgenetic Alopecia

in Treatment 102 upvotes 5 years ago

Hair loss theory suggests imbalance between Vitamin D Receptor (VDR) and Androgen Receptor (AR) activation. Proposed treatment includes upregulating VDR, downregulating AR, and improving mitochondrial health.

community SCUBE3 and GT20029 could be the closet thing to a cure: Hair Follicle Regeneration and Protection Against DHT

in Research/Science 14 upvotes 2 years ago

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

community One year anti androgen update CROWN

in Finasteride/Dutasteride 338 upvotes 2 years ago

User used Finasteride, Dutasteride, and Minoxidil for one year to treat hair loss. They discussed possibly trying RU58841 or pyrilutamide in the future.

community Can I still save my hairline at age of 15?

in General 478 upvotes 3 weeks ago

A 15-year-old is concerned about hair loss, possibly at Norwood 2 or 3, and is using shampoos and conditioners recommended by a trichologist. Suggestions include considering topical minoxidil and consulting a doctor about topical anti-DHT treatments like finasteride or RU58841, but avoiding 5-alpha-reductase inhibitors at this age.

community NMN Promotes Cell Proliferation and Hair Growth by Reducing Oxidative Stress

in Research/Science 13 upvotes 1 year ago

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

community Received Kintor’s KX-826 Today

in Product 84 upvotes 1 year ago

A user received Kintor’s KX-826/Pyrilutamide and shared initial impressions, noting concerns about the product's labeling and marketing. Other users discussed the legitimacy of the product, its effectiveness, and compared it to other treatments like Minoxidil and Finasteride.

Similar Research

6 / 1000+ results

research Androgen Receptor Ligands: Agonists and Antagonists

2 citations , November 2017 in “Elsevier eBooks”

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

research Expression and Function of Nuclear Receptor Co-Activator 4: Evidence of a Potential Role Independent of Co-Activator Activity

26 citations , May 2012 in “Cellular and Molecular Life Sciences”

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

research Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects

35 citations , January 2012 in “The Journal of Sexual Medicine”

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.

Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content

research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content

82 citations , February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.

research Potential Targets in the Discovery of New Hair Growth Promoters for Androgenic Alopecia

59 citations , May 2014 in “Expert Opinion on Therapeutic Targets”

The document concludes that targeting 5α-reductase, the androgen receptor, and hair growth genes, along with using compounds with anti-androgenic properties, could lead to more effective hair loss treatments.

research Androgen Receptor Antagonists Structure-Activity Relationships

204 citations , February 2000 in “Current Medicinal Chemistry”

Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.